{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:44:31Z","timestamp":1766486671839},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Artificial Organs"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite their propensity for significant infectious and mechanical complications, tunneled central venous catheters (<jats:styled-content style=\"fixed-case\">CVC<\/jats:styled-content>s) have become a common means of vascular access in the world for patients requiring chronic hemodialysis for end\u2010stage renal disease. The objective of this study was to explore if cryopreserved solutions of the thrombolytic agent alteplase could be used as an effective, safe, and economically reasonable alternative in hemodialysis patients with occluded tunneled <jats:styled-content style=\"fixed-case\">CVC<\/jats:styled-content>. Patients requiring chronic hemodialysis and presenting with occluded tunneled <jats:styled-content style=\"fixed-case\">CVC<\/jats:styled-content> received a sufficient volume of the alteplase solution to fill the occluded catheter. To make alteplase economically feasible, it was diluted to 1\u2010mg\/mL aliquots and they were stored at \u221220\u00b0C until use. Eighty\u2010one patients accounting for 179 attempted clearances were assessable for efficacy. One hundred forty\u2010seven (82.1%) of the 179 catheter clearance attempts resulted in successful catheter clearance after one dose. Twenty\u2010seven (15.1%) of all occluded <jats:styled-content style=\"fixed-case\">CVCs<\/jats:styled-content> were successful after two doses whereas five (2.8%) were not. No adverse events were reported. Cryopreserved 1\u2010mg\/mL aliquots of alteplase are safe and effective in the clearance of occluded <jats:styled-content style=\"fixed-case\">CVC<\/jats:styled-content> for hemodialysis patients.<\/jats:p>","DOI":"10.1111\/aor.12186","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T02:42:55Z","timestamp":1381545775000},"page":"399-403","source":"Crossref","is-referenced-by-count":14,"title":["Effective Use of Alteplase for Occluded Tunneled Venous Catheter in Hemodialysis Patients"],"prefix":"10.1111","volume":"38","author":[{"given":"Marcela L.","family":"Mendes","sequence":"first","affiliation":[{"name":"Internal Medicine University of S\u00e3o Paulo State\u2014Botucatu School of Medicine\u2014UNESP  Botucatu S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o H.","family":"Castro","sequence":"additional","affiliation":[{"name":"Internal Medicine University of S\u00e3o Paulo State\u2014Botucatu School of Medicine\u2014UNESP  Botucatu S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricya N.","family":"Silva","sequence":"additional","affiliation":[{"name":"Internal Medicine University of S\u00e3o Paulo State\u2014Botucatu School of Medicine\u2014UNESP  Botucatu S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasqual","family":"Barretti","sequence":"additional","affiliation":[{"name":"Internal Medicine University of S\u00e3o Paulo State\u2014Botucatu School of Medicine\u2014UNESP  Botucatu S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Ponce","sequence":"additional","affiliation":[{"name":"Internal Medicine University of S\u00e3o Paulo State\u2014Botucatu School of Medicine\u2014UNESP  Botucatu S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"US Renal Data System.USRDS 2009 Annual Data Report: Atlas of End\u2010Stage Renal Disease in the United States. Bethesda MD: National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases 2009."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0894-0959.2004.17339.x"},{"issue":"1","key":"e_1_2_6_4_1","first-page":"2","article-title":"Doen\u00e7a Renal Cr\u00f4nica no Brasil: um problema de sa\u00fade p\u00fablico","volume":"31","author":"Lugon JR","year":"2004","journal-title":"J Bras Nefrol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90495-3"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.198.1.8539402"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.131"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2009.06.006"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.05.024"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2006.00143.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139x.2001.00109.x"},{"issue":"1","key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0272-6386(01)70007-8","article-title":"NKF\u2010K\/DOQI Clinical Practice Guidelines for Vascular Access: update 2000","volume":"37","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_6_13_1","volume-title":"Activase (Alteplase, Recombinant) [product information brochure]","author":"Genentech Inc","year":"1999"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(07)61575-9"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/57.11.1039"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139X.2003.16060.x"},{"key":"e_1_2_6_17_1","first-page":"547","article-title":"Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double\u2010blind randomized trial","volume":"72","author":"Haire WD","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN107351"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN1407028"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06520909"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011376"},{"key":"e_1_2_6_22_1","first-page":"7","article-title":"Prevention of catheter lumen occlusion with rT\u2010PA versus heparin (Pre\u2010CLOT): study protocol of a randomized trial","volume":"11","author":"Hemmelgarn BR","year":"2006","journal-title":"BMC Nephrol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.10.1031"}],"container-title":["Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faor.12186","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aor.12186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:16:33Z","timestamp":1696461393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aor.12186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/aor.12186"],"URL":"https:\/\/doi.org\/10.1111\/aor.12186","archive":["Portico"],"relation":{},"ISSN":["0160-564X","1525-1594"],"issn-type":[{"value":"0160-564X","type":"print"},{"value":"1525-1594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,3]]}}}